Equity Overview
Price & Market Data
Price: $0.829
Daily Change: +$0.0376 / 4.54%
Range: $0.753 - $0.829
Market Cap: $43,393,220
Volume: 34,108
Performance Metrics
1 Week: -4.67%
1 Month: -1.15%
3 Months: -2.69%
6 Months: -30.27%
1 Year: -53.51%
YTD: -43.41%
Company Details
Employees: 62
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is headquartered in San Diego, California.